Boston, United States
Leuko, founded in 2017, aims to revolutionize medical diagnostics with its non-invasive white blood cell monitoring technology. The company is pioneering the development of the first device capable of assessing white blood cells without the need for blood extraction. This innovation holds significant promise for applications such as chemotherapy management and the early detection of life-threatening infections.
Current methods for white blood cell assessment are invasive, requiring patient travel, blood draws, and lab infrastructure. Leveraging research from MIT, Leuko is transforming these assessments into a portable, non-invasive procedure, thereby increasing accessibility and potentially saving lives.
Operating at the intersection of Biotechnology, Health Care, and Medical Devices, Leuko is headquartered in the United States. Its last investment was a $100.00K grant from MassVentures on June 30, 2021. Investors may find significant potential in backing a company that addresses a critical need in the medical field with ground-breaking technology.
